Scientific article
Open access

Anti-CTLA-4 Monoclonal Antibodies Induced Hypophysitis: Case Report and Literature Review

Published inAnnals of Clinical Case Reports, vol. 2, 1382
Publication date2017

Treatment with Anti-CTLA-4 Monoclonal Antibodies (mAb) has become a common choice in advanced melanoma and is under evaluation for many other types of cancer. These antibodies inhibit the interaction between CTLA-4 (Cytotoxic T Lymphocyte-Associated Antigen 4) receptors on the T cell surface and the antigen presenting cell surface molecules B7, leading to the activation or enhancement of T cell immune responses. The oncologic beneficial effects of Anti-CTLA-4 mAb are marred by many immune related adverse effects, including Ipilimumab-Induced Hypophysitis (IIH). We, herein, report an illustrative case with a literature review. Based on this research, the incidence of IIH was between 1.75% and 13%. Presenting symptoms were predominantly headache and fatigue. Pituitary enlargement was the main radiologic sign on MRI. The thyrotrophic and adrenocorticotropic axes were the most commonly affected followed by gonadotropic, somatotropic and lactotropic axes, respectively. Time to hypophysitis onset varied between 5 and 40 weeks after starting ipilimumab and treatment withdrawal due to hypophysitis was largely variable. Finally, thyrotropin and gonadotropin axes recovered more frequently than other anterior pituitary axes.

Citation (ISO format)
JAAFAR, Jaafar, PHILIPPE, Jacques. Anti-CTLA-4 Monoclonal Antibodies Induced Hypophysitis: Case Report and Literature Review. In: Annals of Clinical Case Reports, 2017, vol. 2, p. 1382.
Main files (1)
Article (Published version)
  • PID : unige:98938
ISSN of the journal2474-1655

Technical informations

Creation11/14/2017 12:09:00 PM
First validation11/14/2017 12:09:00 PM
Update time03/15/2023 2:20:02 AM
Status update03/15/2023 2:20:02 AM
Last indexation08/30/2023 5:12:50 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack